Mark Bagnall

CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Forticell Bioscience, Inc. focuses on advanced regenerative medicine and stem cell therapy. The company was founded in 1991 and is headquartered in Englewood Cliffs, NJ.

GENTURAdx USA, Inc. manufactured biotechnology instruments. The firm provided tools necessary for detection and treatment of diseases and drug discoveries. It had offices in the Silicon Valley, Hong Kong, Shanghai and Suzhou. The company was founded by Steve Yu and Jesus Ching in June 2005 and was headquartered in Hayward, CA.

Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA.

Metrika Inc. manufactures and markets disease-monitoring products. It also manufactures other chronic condition products. The company was founded in 1994 by Michael P. Allen and is headquartered in Sunnyvale, CA.

Progenitor, Inc. is an American private company. The firm develops pharmaceutical compounds for nervous system. The company is headquartered in Columbus, OH.

Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA